Search
CorMedix Inc
CRMDAdd to Watchlist
7.770USD
+0.080+1.04%
Close 09-24 16:00（ET）
609.56MMarket Cap
3.19P/E TTM
About CorMedix Inc Company
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
CorMedix Inc Profile
Ticker SymbolCRMD
Company nameCorMedix Inc
IPO dateMar 25, 2010
CEOTodisco (Joseph)
Number of employees64
Security typeOrdinary Share
Fiscal year-endMar 25
Address300 Connell Drive
CityBERKELEY HEIGHTS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07922
Phone19085179500
Websitehttps://cormedix.com/
Ticker SymbolCRMD
IPO dateMar 25, 2010
CEOTodisco (Joseph)
Company Executives of CorMedix Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
401.08K
-41.48%
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
401.08K
-41.48%
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
401.08K
-41.48%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-4.27%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-4.27%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-4.27%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
124.31K
-6.78%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
124.31K
-6.78%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
124.31K
-6.78%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
87.38K
+55.97%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
401.08K
-41.48%
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
401.08K
-41.48%
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
401.08K
-41.48%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-4.27%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-4.27%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-4.27%
FAQs
Who are the top five shareholders of CorMedix Inc?
The top five shareholders of CorMedix Inc are: Mr. Joseph (Joe) Todisco
How many institutions hold shares of CorMedix Inc (CRMD)?
As of 2026Q1, 390 institutions hold shares of CorMedix Inc, with a combined market value of approximately 43.28M, accounting for 55.17% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -18630389.00.